A Chinese-made coronavirus vaccine may be ready for the market by the end of this year, the Chinese state asset monitoring and management commission (SASAC) said in a social media post.
In studies, more than 2,000 people have received vaccines developed by the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products. According to the May 29 article on the Chinese social media platform WeChat, a vaccine could be ready for the market by the end of this year or early 2021.
Vaccines from the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products had entered phase II clinical trials. Both groups are associated with the state-owned pharmaceutical company Sinopharm, whose management is monitored by SASAC.
The Beijing Institute of Biological Products production line will have an annual production capacity of 100 million to
120 million cans according to the article.
China has five coronavirus vaccines in human trials. None of the companies could be reached for comment on Saturday evening.